{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:26:55Z","timestamp":1767652015962},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.euroneuro.2009.07.009","type":"journal-article","created":{"date-parts":[[2009,8,30]],"date-time":"2009-08-30T08:19:40Z","timestamp":1251620380000},"page":"841-850","source":"Crossref","is-referenced-by-count":11,"title":["BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans"],"prefix":"10.1016","volume":"19","author":[{"given":"Lieuwe","family":"Appel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yona","family":"Geffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Heurling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shitij","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.07.009_bib1","first-page":"657","article-title":"A rapid and accurate method to realign PET scans utilizing image edge transformation","volume":"36","author":"Andersson","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/syn.890150405","article-title":"Dopamine-immunoreactive axon varicosities form nonrandom contacts with GABA-immunoreactive neurons of rat medial prefrontal cortex","volume":"15","author":"Benes","year":"1993","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.41.1.237","article-title":"Interactions between monoamines, glutamate and GABA in schizophrenia, new evidence (Review)","volume":"41","author":"Carlsson","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","article-title":"Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings","volume":"46","author":"Dahl-Puustinen","year":"1989","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archpsyc.1988.01800250087012","article-title":"Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs","volume":"45","author":"Farde","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2008.07.002","article-title":"BL-1020, a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia","volume":"19","author":"Geffen","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-005-2212-8","article-title":"GABAergic dysfunction in schizophrenia, new treatment strategies on the horizon (Review)","volume":"180","author":"Guidotti","year":"2005","journal-title":"Psychopharmacology"},{"issue":"Suppl","key":"10.1016\/j.euroneuro.2009.07.009_bib9","doi-asserted-by":"crossref","first-page":"329S","DOI":"10.1016\/0197-0186(92)90260-X","article-title":"Imaging of dopamine receptors using PET and SPECT (Review)","volume":"20","author":"Hall","year":"1992","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.npp.1380111","article-title":"Distribution of D1 and D2 dopamine receptors, and dopamine and the metabolites in the human brain","volume":"11","author":"Hall","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0009-9236(96)90111-3","article-title":"The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol","volume":"59","author":"Jerling","year":"1996","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D (2) occupancy, clinical response, and side effects: a double blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0091-3057(98)00133-6","article-title":"The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine","volume":"61","author":"Karler","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0028-3908(71)90013-X","article-title":"Blood\u2013brain barrier to H3-gamma-aminobutyric acid in normal and amino oxyacetic acid-treated animals","volume":"10","author":"Kuriyama","year":"1971","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","article-title":"Simplified reference tissue model for PET receptor studies","volume":"4","author":"Lammertsma","year":"1996","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica Suppl"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hup.470070302","article-title":"PET analysis of central [11C]raclopride binding in healthy young adults and schizophrenic patients \u2014 reliability and age effects","volume":"7","author":"Nordstr\u00f6m","year":"1992","journal-title":"Hum. Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0006-3223(93)90288-O","article-title":"Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients","volume":"33","author":"Nordstr\u00f6m","year":"1993","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib21","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/jm7012453","article-title":"A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects","volume":"51","author":"Nudelman","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib22","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib23","first-page":"236","article-title":"GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats","volume":"278","author":"Shukla","year":"1985","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.euroneuro.2009.07.009_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00213-004-1802-1","article-title":"A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration","volume":"175","author":"Talvik","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2009.07.009_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/01.jcp.0000095349.32154.a5","article-title":"GABA and schizophrenia, a review of basic science and clinical studies","volume":"23","author":"Wassef","year":"2003","journal-title":"J. Clin. Psychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09001916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X09001916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T12:54:27Z","timestamp":1545051267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X09001916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0924977X09001916"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.07.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}